Pharma BD Deal Intelligence
A $1.65B upfront co-development deal (up to $5.3B total) that hands Roche petrelintide, an amylin analog obesity asset, betting on Zealand Pharma's science to compete in the crowded weight-loss race—outcome still unfolding this early in the partnership.
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people…
Pharmalittle: We're reading about a Roche deal for an obesity drug, a Gilead HIV drug and more. Roche is paying $1.65 billion upfront to license amylin analog…
New data from the Phase 2 ZUPREME-1 trial presented at the American Diabetes Association 2026 Scientific Sessions further support petrelintide's…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Roche partnered with Zealand Pharma to co-develop petrelintide, an amylin analog for obesity, paying $1.65B upfront in a deal worth up to $5.3B.
T2D + obesity co-morbid population is the highest-value obesity segment and is dominated by incretins. GLP-1 receptor agonists: Ozempic (semaglutide, Novo Nordisk, FDA-approved T2D 2017) grossed DKK 120B+ in 2024 across T2D indications; Trulicity (dulaglutide, Lilly) and Victoza (liraglutide, Novo, now generic) round out the class. GLP-1/GIP dual agonists: Mounjaro (tirzepatide, Eli Lilly, approved 2022 for T2D) with $11.5B 2024 sales; SURPASS-2 showed -2.30% HbA1c and -12.4 kg weight loss. Triple agonists: retatrutide (Lilly, Phase 3) demonstrated HbA1c -2.16% and 17% weight loss in T2D Phase 2. Amylin analogs: Symlin (pramlintide, AstraZeneca, approved 2005) is the only on-market amylin, mealtime-dosed with ceiling weight effect; Petrelintide (Zealand/Roche, weekly, Phase 2b) is positioned as GLP-1 alternative/complement. SGLT2 inhibitors: Jardiance (empagliflozin, Boehringer/Lilly) and Farxiga (dapagliflozin, AstraZeneca) contribute modest weight loss with CV/renal benefits. Commercial read: Petrelintide must demonstrate either additive HbA1c/weight benefit on top of GLP-1 or meaningful GI-tolerability advantage to win share in a category where Lilly and Novo control >80%.
Fixed-dose and co-administration obesity combinations segment by MOA synergy. Amylin + GLP-1 combinations: CagriSema (cagrilintide + semaglutide, Novo Nordisk, Phase 3 REDEFINE program) is the lead comparator, with REDEFINE-1 reporting 22.7% weight loss at 68 weeks (below the 25% guidance target, creating commercial headroom); Petrelintide + CT-388 (Zealand/Roche amylin + GLP-1/GIP) is the direct fixed-dose analog at Phase 2. GLP-1/GIP dual agonists as monotherapy combinators: Zepbound (tirzepatide, Eli Lilly) sets the efficacy bar at 22.5% weight loss (SURMOUNT-1). Triple agonists (GLP-1/GIP/glucagon): retatrutide (Lilly, Phase 3 TRIUMPH) at ~24% weight loss Phase 2; survodutide (Boehringer Ingelheim/Zealand, Phase 3) showed 18.7% at 46 weeks. Glucagon/GLP-1 duals: mazdutide (Innovent, Phase 3 China). GLP-1/amylin unimolecular: amycretin (Novo, Phase 1 oral + SC) shows early best-in-class potential (22% at 36 weeks Phase 1b). Commercial read: Roche + Zealand must out-execute Novo's CagriSema on tolerability and dose titration simplicity; the fixed-dose combination window is narrowing as unimolecular multi-agonists mature.
The obesity market is GLP-1-dominated with escalating MOA complexity across six active mechanism classes. GLP-1 receptor agonists: Wegovy (semaglutide 2.4mg weekly SC, Novo Nordisk, FDA-approved June 2021) generated DKK 58.2B in 2024 Novo net sales with MACE benefit label expansion; Saxenda (liraglutide daily, Novo) is the older daily product losing share to weekly peers. GLP-1/GIP dual agonists: Zepbound (tirzepatide, Eli Lilly, approved November 2023) reached $4.9B in 2024 net sales with SURMOUNT trials showing approximately 22% weight loss at 72 weeks. Triple agonists (GLP-1/GIP/glucagon): retatrutide (Lilly, Phase 3 TRIUMPH program) demonstrated approximately 24% weight loss at 48 weeks in Phase 2 (NEJM 2023). Oral small-molecule GLP-1: orforglipron (Lilly, Phase 3 ATTAIN) and oral semaglutide 25-50mg (Novo, OASIS-1 positive) target the non-injectable segment. Amylin analogs: cagrilintide (Novo, Phase 3 as fixed-dose co-formulation with semaglutide = CagriSema, REDEFINE trials); Petrelintide (Zealand/Roche, Phase 2b) positions as GLP-1-sparing monotherapy with weekly dosing. Legacy oral agents: Contrave (naltrexone/bupropion, Currax) and Qsymia (phentermine/topiramate, Vivus) retain small oral share. Commercial read: amylin monotherapy must demonstrate differentiated tolerability (lower GI burden) or weight-loss-maintenance profile versus the GLP-1 class to carve share in an increasingly commoditized and supply-constrained market.
Roche and Zealand Pharma closed their exclusive collaboration and license agreement (announced 12 Mar 2025; closed Q2 2025) to co-develop and co-commercialize petrelintide, an amylin analog, as a foundational obesity therapy in the US and EU. Zealand received $1.65B upfront ($1.4B at closing + $250M anniversary payments over two years); total consideration up to $5.3B with 50/50 US/EU profit sharing. This is a partnership, not an acquisition of Zealand Pharma.
ZUPREME-1 met primary endpoint but investors disappointed by modest efficacy vs competitors.
Roche and Zealand decided to advance petrelintide to Phase 3 for chronic weight management (initiation planned H2 2026) after positive ZUPREME-1 Phase 2 results; a petrelintide/enicepatide (CT-388) combination Phase 2 is planned for Q2 2026.
Assessment of Roche's up-to-$5.3B co-development/licensing collaboration with Zealand Pharma for petrelintide. Following positive ZUPREME-1 Phase 2 results (Mar 2026) and the decision to advance to Phase 3 (Apr 2026), the thesis has strengthened versus the initial mixed reception. This is a partnership, not an acquisition of Zealand Pharma.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Zealand Pharma A/S (this deal) | 2025 | $5.3B | 63 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2025 deals · Roche Holding AG deals · Metabolic deals